Print this page
-
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Other Male Genital
Other Female Genital -
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
- Marissa Botwinick MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.
Protocol: 111914Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Any Site -
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies.
Protocol: 072014Principal Investigator:
- Seth Cohen MD (Monmouth Medical Center)
Applicable Disease Sites: Any Site -
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System